Home > Boards > US OTC > Medical - Drugs >

Advanced Cell Technology (ACTC)

Add ACTC Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator locksflooring, sports guy, Kapla, LODE MAKING ME RICH, homeslice10, lasers
Search This Board:
Last Post: 7/23/2014 10:26:53 PM - Followers: 633 - Board type: Free - Posts Today: 0

Advanced Cell Technology, Inc. (ACTC)







Company Headquarters:

Advanced Cell Technology, Inc.
P.O. Box 1700
Santa Monica, CA 90406

Tel: (310) 576 0611
Fax: (310) 576 0662



Massachusetts Laboratory Facility
33 Locke Dr.
Marlborough, MA 01752
Tel: (508) 756-1212
Fax: (508) 229-2333


Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC) is a biotechnology company developing cellular therapies for the treatment of diseases that impact millions of people worldwide. The company is currently conducting the only ongoing, FDA-cleared human embryonic stem cell (hESC)-based human clinical trials. The two trials, initiated in July 2011 at UCLA's Jules Stein Eye Institute, use retinal pigment epithelial (RPE) cells derived from hESCs to treat forms of macular degeneration. ACT also recently received approval from the UK Medicines & Healthcare Products Regulatory Agency (MHRA) to conduct the first hESC trial in Europe. The company is also developing its Hemangioblast (HG) platform for the treatment of blood and cardiovascular diseases, its Phase II-cleared Myoblast stem cell therapy for the treatment of chronic heart failure and other cardiac conditions, and other programs.

ACT's principal laboratory and GMP facility is in Marlborough, Massachusetts, and its corporate offices are in Santa Monica, California. ACT is led by an experienced management team and a world-class scientific team helmed, respectively, by interim chairman and CEO Gary Rabin and chief scientific officer Robert Lanza, M.D.


ACT owns or licenses more than 150 patents and patent applications related to stem cell therapy and regenerative medicine, and is positioning itself to have a dominant patent position around its stem cell-derived RPE program in leading markets around the world.
In 2010 ACT secured three far-reaching patents related to its RPE program, and more recently was issued the first patent for generating hemangioblast cells to treat a broad spectrum of vascular and hematopoietic disorders.

The company's RPE and HG programs are hESC-based, and its Myoblast program for cardiac disease is an adult autologous stem cell therapy. As documented in NATURE and Cell Stem Cell, ACT developed the "single-cell blastomere" technique, the first-ever proven alternative method for successful hESC generation without harm to the embryo, for which it was recently issued a broad patent
RPE Program - ACT has developed a fully-differentiated RPE cell derived from human embryonic stem cells, which can be used as a cellular therapy to treat retinal degenerative diseases. In July 2011 ACT initiated two Phase I/II clinical trials to test the safety of the therapy for Stargardt's Macular Dystrophy (SMD), and for Dry Age-Related Macular Degeneration (Dry AMD). Dry AMD represents a $25-30 Billion market in the US and Europe alone, and there are no approved therapies currently available for either condition. Two patients have thus far been treated at UCLA, Institutional Review Board (IRB) approval for the SMD clinical trial has also been issued by Oregon Health & Science University (OHSU) and European regulatory clearance has been granted to initiate the first hESC trial in Europe.
Other recent milestones in ACT's RPE program include: the NIH proposed expanding its definition of hESCs for funding purposes, in part to accommodate ACT's lines derived using its patented "embryo-safe" single-cell blastomere technique; and both the FDA and the European Medicines Agency (EMA) granting ACT's RPE cells "Orphan" status for treatment of Stargardt's Disease.
Hemangioblast Program - ACT's Hemangioblast program is for the treatment of blood and cardiovascular diseases. A paper published in NATURE Methods revealed the company's successful generation of functional Hemangioblast cells from human embryonic stem cells, and a paper published earlier this year in Cell Research indicated that hESCs could be a potentially unlimited source of platelets for transfusion.
Myoblast Program - ACT's Myoblast treatment may prove particularly beneficial for patients who have experienced a serious heart attack and are at risk for heart failure. ACT has secured FDA approval to commence with Phase II clinical trials. The Myoblast program has several advantages over currently-available approaches, including symptom management and disease modification.

Dr. Lanza explains some of the technology we are pursuing: http://www.youtube.com/watch?v=MPBiNlUFIww#t=55s

For more information visit www.AdvancedCell.com




Share Structure as of November 30, 2011:

Outstanding Shares

Reserved Shares

Authorized and Unreserved Shares



Authorized Preferred Shares



The following table sets forth information regarding beneficial ownership of our capital stock as of November 30, 2011 by:

·  5% or greater stockholders;
·  Each of our directors and named executive officers; and
·  All of our directors and executive officers, as a group.


Name and Address (1) of Beneficial Owner                                                                                         Common Stock Beneficially Owned                   Percentage of Shares Beneficially Owned 
5% or Greater Stockholders
Directors and Named Executive Officers
William M. Caldwell, IV**                                                                                                                             95,415,141 (1)                                                           5.58%%

Robert P. Lanza, M.D.                                                                                                                                  51,199,082 (2)                                                           2.97%%

Alan C. Shapiro                                                                                                                                           20,150,927 (3)                                                           1.18%%
Erkki Ruoslahti                                                                                                                                            2,500,000 (4)                                                                *
Gary Rabin                                                                                                                                                 23,087,430 (5)                                                           1.35%
Directors and Executive Officers as a Group (5 Persons)                                                                                192,352,580                                                               11.08%%


* Less than 1%

** Mr. Caldwell passed away on December 13, 2010

(1) Includes 5,108,546 shares subject to stock options that are currently exercisable or exercisable within 60 days of November 30, 2011.

(2) Includes 17,583,207 shares subject to stock options that are currently exercisable or exercisable within 60 days of November 30, 2011.

(3) Includes (i) 17,032,587 shares subject to convertible debentures, board fees, common stock grant held by The Shapiro Family Trust and of
which Dr. Shapiro may be deemed the beneficial owner, (ii) 3,018,340 shares subject to warrants in connection with the 2005-2008
convertible debentures, and (iii) 100,000 shares subject to stock options that are currently exercisable or exercisable within 60 days of
November 30, 2011.

(4) Includes 100,000 shares issuable upon exercise of options exercisable within 60 days of November 30, 2011. Effective August 1, 2011,
Erkki Ruoslahti resigned from the Board of Directors of the Company.

(5) Includes indirect ownership of (i) 1,239,501 shares issued to PDPI, LLC on December 22, 2010, upon exercise of certain warrants, which
such number of shares represents Mr. Rabin's proportional interest in the total number of shares held by PDPI, LLC, based on his 33.33%
equity interest in the entity. Mr. Rabin disclaims beneficial ownership in the shares held by PDPI, LLC, and (ii) 7,000,000 shares subject
to stock options that are currently exercisable or exercisable within 60 days of November 30, 2011.

There are no arrangements known to the Company, including any pledge by any person of securities of the Company, the operation of
which may at a subsequent date result in a change in control of the Company.

Media Relations

Bill Douglass
Gotham Communications, LLC
bill [at] gothamcomm [dot] com


Martina Schwarzkopf, Ph.D.
Russo Partners, LLC
(212) 845-4292
martina.schwarzkopf [at] russopartnersllc [dot] com

Investor Relations

James Young
jyoung [at] ceocast [dot] com
(212) 732-4300






All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.




Rules of the board according to IHUB:


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
ACTC News: OTC Stocks Daily Trading Focus: Windstream Technologies, Inc. Blue Earth, Inc. Creative Edge Nutrition, Inc. Brainstorm Cell ... 07/01/2014 08:00:00 AM
ACTC News: OTC Stocks Daily Trading Focus: Windstream Technologies, Inc. Blue Earth, Inc. Creative Edge Nutrition, Inc. Brainstorm Cell ... 07/01/2014 08:00:00 AM
ACTC News: Current Report Filing (8-k) 05/29/2014 05:00:40 PM
ACTC News: Quarterly Report (10-q) 05/08/2014 04:41:06 PM
ACTC News: Amended Annual Report (10-k/a) 04/29/2014 04:36:14 PM
#67180  Sticky Note $ACTC's May2014 Presentation Posted since on $ACTC website. Enjoy! lasers 06/06/14 12:22:51 AM
#69719   This one is beyond me. elysse1kittycat 07/23/14 10:26:53 PM
#69718   How much can they squeeze out of 30 Gastrodamas 07/23/14 09:53:11 PM
#69717   Money in the bank and looking to pick Gastrodamas 07/23/14 09:49:50 PM
#69716   lincoln park is a serious financial situation. Gastrodamas 07/23/14 09:34:04 PM
#69715   Would this be considered ACTC OTC OCD? Change Trader Joey 07/23/14 09:18:19 PM
#69714   Lincoln Park demands .08 cents. Gastrodamas 07/23/14 09:17:24 PM
#69713   Yes lincoln park and all the Crooked Cronies Gastrodamas 07/23/14 09:16:32 PM
#69712   As I have said before, hopefully some day elysse1kittycat 07/23/14 08:02:43 PM
#69711   Ignore ddls and this will be a much gogrums 07/23/14 07:45:39 PM
#69710   Imo that is why I don' think he elysse1kittycat 07/23/14 07:42:04 PM
#69708   The REAL truth is that the talent and elysse1kittycat 07/23/14 06:35:20 PM
#69707   Jeez......really? Burrhead1 07/23/14 06:01:31 PM
#69706   Advanced Cell Technology's Ace Sales Staff 24-7...7-24???!!! ddls 07/23/14 05:46:47 PM
#69705   Crawford-I agree on everything except the bit on elysse1kittycat 07/23/14 04:08:40 PM
#69704   First of all, I'd like to make a letj21 07/23/14 04:04:11 PM
#69703   $ACTC Blood Platelet Patent Appl would very valuable lasers 07/23/14 03:59:56 PM
#69702   elysse, you are spot on as well. In crawford2012 07/23/14 03:57:14 PM
#69700   Spot on post as usual Crawford, and anyone elysse1kittycat 07/23/14 03:50:22 PM
#69699   Not to toot my own horn, but I elysse1kittycat 07/23/14 03:46:26 PM
#69698   As we beging to see more intense articles, crawford2012 07/23/14 03:43:56 PM
#69697   I'm sure ACTC will be green at the ddls 07/23/14 03:37:23 PM
#69696   Same here, there may be some selling from Auger08 07/23/14 03:36:22 PM
#69695   DiDdllesLittleStick is right, Run for your life!!! rumper 07/23/14 03:35:36 PM
#69694   Advanced Cell Technology investors dollar dream fading out ddls 07/23/14 03:29:21 PM
#69693   Yeah with less volume... looks like a set up. SRSKinvested 07/23/14 03:27:01 PM
#69692   ADVANCED CELL PAYS OVER $4M FOR STOCK SCHEME ddls 07/23/14 03:24:24 PM
#69691   Actually, Cisco, it would've been a bit sad elllk 07/23/14 03:23:44 PM
#69689   .04-.12 range is all pretty meaningless to me... beninsac 07/23/14 03:18:44 PM
#69688   ACTC a Penny Stock It Thus Remains ddls 07/23/14 03:18:22 PM
#69686   Advanced Cell Technology ACTC GROOMS NEW SET OF ddls 07/23/14 03:16:06 PM
#69685   pps sure goes down faster then up. guy3 07/23/14 03:12:12 PM
#69684   Advanced Cell Technology has financed themselves to the ddls 07/23/14 03:09:41 PM
#69682   WE CONTINUE TO PAY OUR DEBT financings in ddls 07/23/14 03:07:38 PM
#69681   Advanced Cell Technology has a plan for investors ddls 07/23/14 03:04:12 PM
#69680   Probability Of Success "POS" is high with all chuckanutman 07/23/14 03:03:13 PM
#69679   The expert clear and concise Advanced Cell Technology ddls 07/23/14 02:55:45 PM
#69678   Hang in there newbie, we get another day tsoprano-1 07/23/14 02:53:39 PM
#69677   Do Macular Degeneration patients loose or is their chuckanutman 07/23/14 02:49:40 PM
#69676   Deeds wins today, it looks like! homeslice10 07/23/14 02:48:21 PM
#69675   Wow, what is happening today? I was thinking Haynzy15 07/23/14 02:40:18 PM
#69674   Anything is possible includes a bounce up. chuckanutman 07/23/14 02:31:15 PM
#69673   Aren't we down? Cisco_Tajuara 07/23/14 02:28:11 PM
#69672   $$$$$$$$ ACTC $$$$$$$$ beninsac 07/23/14 02:27:24 PM
#69671   I'm glad to see that mess cleaned up. SRSKinvested 07/23/14 02:02:12 PM
#69670   IMO, that will easily come as we begin farviewhill 07/23/14 01:58:53 PM
#69669   "Build it and they shall come!" elysse1kittycat 07/23/14 01:30:53 PM
#69668   We still need additional financing before we can SRSKinvested 07/23/14 12:56:38 PM
#69667   A_Million Shares is_only_a boat and new car, $82,000 rumper 07/23/14 12:33:12 PM
#69666   The other side of the coin is that elysse1kittycat 07/23/14 12:16:14 PM